So Entresto is ready to be rolled out in the US with a price tag of around $4,500 a year. Novartis has hinted at an outcomes-based pricing plan but there are no details of any scheme or how it ...

Novartis’ Entresto is on course to become the first drug to be approved in the US for a form of heart failure that is notoriously hard to treat effectively, despite missing the mark in a phase 3 ...

With the new manufacturing capacity, 100% of its key medicines for U.S. patients will be made in the U.S., Novartis said late ...

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a ...

Novartis' drugs, including heart failure medicine Entresto and breast cancer therapy Kisqali, are manufactured across 33 sites globally. The new sites and extensions will be built over the next five ...

Sacubitril, valsartan; 6mg/6mg, 15mg/16mg; oral pellets in caps. Entresto Sprinkle is supplied as film-coated oral pellets are round, biconvex in shape, and provided in a hard capsule in the ...

As Fierce Pharma points out, patent expirations are a routine occurrence in the pharmaceutical world, but 2025 stands out for the unusually large number of drugs affected. Among the companies facing ...

NVS' first-quarter performance has likely benefited from strong growth in Kisqali, Kesimpta, Pluvicto, Leqvio, Scemblix and ...

The pharmaceutical sector has been making headlines for large-scale layoffs, department closures and clinical trial failures.

A three-judge panel wrestled Thursday with Novartis AG’s challenge against the FDA over its approval of a generic version of ...

After Novartis’ patent on the blockbuster blood pressure medication Entresto was found invalid at the district court for covering technology that was developed after the patent was filed ...